← back to search

Ralph Weissleder

Harvard University · US
Area of research
Molecular Biology · Biomedical Engineering
Research interest
Research interests include Nanoplatforms for cancer theranostics, Advanced biosensing and bioanalysis techniques, Immune cells in cancer, and Nanoparticle-Based Drug Delivery.
h-index
201
citations
171,962
works
1,598
NIH funding
primary concept
email

Recent publications

Supplementary Data1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
2026cited by 0position: contributordoi
Table S1 - Representation1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
2026cited by 0position: contributordoi
Supplementary Data2 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
2026cited by 0position: contributordoi
Data from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
2026cited by 0position: contributordoi
Intramolecular control of click-to-release chemistry unlocks fast and quantitative bioorthogonal bond cleavage in living systems
2026cited by 0position: contributordoi
Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models
Nature Biotechnology 2026cited by 0position: contributordoi
Erasable FAP Targeted Spray‐On Probe for Fluorescence‐Guided Surgery
Advanced Science 2026cited by 0position: contributordoi
DEG table1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
2026cited by 0position: contributordoi
Advances and challenges in precision imaging
The Lancet Oncology 2025cited by 36position: lastdoi
Fluorinated Ribonucleocarbohydrate Nanoparticles Allow Ultraefficient mRNA Delivery and Protein Expression in Tumor-Associated Myeloid Cells
Journal of the American Chemical Society 2025cited by 8position: contributordoi
Ex vivo machine perfusion as a platform for lentiviral gene delivery in rat livers
Gene Therapy 2025cited by 7position: contributordoi
Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence
Nature Biomedical Engineering 2025cited by 7position: contributordoi
Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities
Biotechnology Advances 2025cited by 7position: middledoi
Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer
Cell Reports Medicine 2025cited by 5position: contributordoi
Targeting cancer-associated fibroblasts for real-time intraoperative tumor identification with a spray-on fluorescent probe
Science Advances 2025cited by 4position: contributordoi
Fluorescent PSMA-Targeted Radiotheranostic Compounds for Multiscale Imaging
Bioconjugate Chemistry 2025cited by 3position: contributordoi
Next-Level Bioorthogonal Bond-Cleavage Through Intramolecular Control of Click-To-Release Chemistry
2025cited by 2position: contributordoi
Far-Red Spray-On Imaging Probes for FAP-Targeted Cancer Surgery
Bioconjugate Chemistry 2025cited by 1position: contributordoi
Radiation-Triggered Payload Release Enhances Bispecific Antibody Efficacy
Cancer Research 2025cited by 0position: contributordoi
Data from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
2025cited by 0position: contributordoi
Supplementary Figure S5 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
2025cited by 0position: contributordoi
A Myeloid Cell-Targeted Immunostimulant Cocktail (MyTai) Enhances Cancer Immunotherapy
ACS Nano 2025cited by 0position: contributordoi
Supplementary Table S2 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
2025cited by 0position: contributordoi
Supplementary Figure S6 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
2025cited by 0position: contributordoi
Integrated Multi‐Channel Automatic Cellular Profiling (iMAP) System for Cholangiocarcinoma Diagnosis
Small 2025cited by 0position: contributordoi
Supplementary Figure S1 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
2025cited by 0position: contributordoi
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Clinical Cancer Research 2025cited by 0position: contributordoi
Supplementary Figure S3 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
2025cited by 0position: contributordoi
Supplementary Figure S4 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
2025cited by 0position: contributordoi
Supplementary Figure S2 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 153 papers (2019–2026)Miles A. Miller · Brigham and Women's Hospital74 papers (2019–2025)Ran Li · Kunming Medical University67 papers (2019–2025)Thomas S.C. Ng · Boston University66 papers (2020–2025)Jeremy M. Quintana · University of Geneva64 papers (2022–2025)Ella Scott · Center for Systems Biology63 papers (2022–2025)Huiyu Hu · Centre de Recherche en Santé de Nouna63 papers (2022–2025)Sareh Parangi · Newton Wellesley Hospital62 papers (2022–2025)Dylan Matvey · Center for Systems Biology62 papers (2022–2025)Mikyung Kang · Dongguk University Ilsan Hospital61 papers (2023–2025)Venkata R. Vantaku · Baylor College of Medicine61 papers (2023–2025)Matthias Nahrendorf · Harvard University27 papers (2012–2022)Filip K. Świrski · Allen Institute for Brain Science25 papers (2012–2022)Yoshiko Iwamoto · Harvard University24 papers (2012–2018)Rainer Kohler · Harvard University20 papers (2019–2026) · 19 papers (2012–2020)Mikäel J. Pittet · University of Geneva18 papers (2012–2023)Gregory R. Wojtkiewicz · Harvard University14 papers (2013–2022)Peter Libby · Harvard University13 papers (2012–2017)Gabriel Courties · Inserm12 papers (2013–2018)